Uppsala
over 25 years old
Healthy individualsStudy 1015
We are looking for people with obesity to participate in a drug trial. The study is evaluating a drug currently in development for obesity.
Obesity is a growing problem worldwide and increases the risk of cardiovascular disease, among other conditions.
The purpose of the study is to investigate the drug’s safety and tolerability, how it is absorbed,
distributed, and excreted in the body, as well as its effect following repeated dosing.
Target group: men and infertile/postmenopausal women who are overweight, over the age of 25
Criteria for participation:
- BMI between 30 and 39.9 kg/m²
- Stable weight over the past 3 months
- Be healthy
- Unused medication that lowers blood sugar and may affect weight
in the past year - Has not been treated with weight-loss medication or participated in a weight-loss program
in the past three months - Do not use tobacco or nicotine products on a regular basis
- Must not have participated in another drug study in the last three months
- Have not donated blood in the past three months
- Be willing to use dual protection during heterosexual intercourse (men)
- Be infertile or postmenopausal (women)
The study consists of 13 visits to our clinic in Uppsala, as well as two visits in Stockholm, over a period of approximately 18 weeks. The first visit is a health checkup. Between visits 2 and 12, you will take the study medication or
placebo twice daily. During four of the visits, you will stay overnight at the clinic for two
days; the remaining visits are outpatient visits. The final visit is a concluding follow-up visit.
Compensation:
You will receive 30,960 SEK as compensation for your participation, as well as travel expenses.
Schedule
| GROUP | Health Checkup (Visit 1) | Visit 1 in Stockholm | Admitted to the clinic (visit 2) | Visit 3 | Admitted to the clinic (visit 4) | Visit 5 | Admitted to the Clinic (visit 6) | Visit 7 | Admitted to the Clinic (visit 8) | Visit 9 | Visit 10 | Visit 11 | Visit 12 | Follow-up visit (visit 13) |
| 1 | Sept. 30 | Oct. 5, 6, or 8 | Oct. 12–14 | Oct. 16 | Oct. 19–21 | Oct. 23 | Oct. 26–28 | Oct. 30 | Nov. 2–4 | Nov. 6 | Nov. 9 | Dec. 7 | Jan. 4, 2027 | Jan. 18, 2027 |
| 2 | Oct. 5 | Oct. 19, 20, or 22 | Oct. 29–Nov. 1 | Nov. 2 | Nov. 5–7 | Nov. 9 | Nov. 12–14 | November 16 | Nov. 19–21 | Nov. 23 | Nov. 26 | Dec. 23 | Jan. 21, 2027 | Feb. 4, 2027 |
| 3 | Oct. 15 | Nov. 2 or 3 | Nov. 9–11 | November 13 | Nov. 16–18 | November 20 | Nov. 23–25 | Nov 27 | Nov. 30–Dec. 2 | Dec. 4 | Dec. 7 | Jan. 4, 2027 | February 1, 2027 | Feb. 15, 2027 |
More information and registration
Would you like to participate in the study?Please submit an expression of interest using the form below.
Do you have any questions or want to know more?Call 018-30 33 99 or emailinfo@ctc-ab.se.
The study has been approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency. Your participation is voluntary, and you may withdraw at any time. The information you provide will be processed in accordance with the General Data Protection Regulation (GDPR).
